Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes

被引:50
作者
Woodruff, TM [1 ]
Strachan, AJ
Sanderson, SD
Monk, PN
Wong, AK
Fairlie, DP
Taylor, SM
机构
[1] Univ Queensland, Dept Physiol & Pharmacol, St Lucia, Qld 4067, Australia
[2] Univ Queensland, Ctr Drug Design & Dev, St Lucia, Qld 4067, Australia
[3] Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England
[4] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE USA
基金
英国医学研究理事会;
关键词
C5a antagonist; C5a agonist; leukocytes;
D O I
10.1023/A:1011036414353
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
This study investigated the receptor binding affinities of a C5a agonist and cyclic antagonists for polymorphonuclear leukocytes (PMNs) isolated from human, sheep, pig, dog, rabbit, guinea pig, rat and mouse. The affinities of the two small molecule antagonists, F-[OPdChaWR] and AcF-[OPdChaWR], and the agonist, YSFKPMPLaR, revealed large differences in C5a receptor (C5aR) affinities between species. The antagonists bound to human, rat and dog PMNs with similar high affinities, but with lower affinities to PMNs from all other species. The C5a agonist also bound with varying affinities between species, but showed a different affinity profile to the antagonists. In contrast, recombinant human C5a had similar affinity for PMNs of all species investigated. The low correlation between the affinities of the antagonists and the agonist between species either suggests that different receptor residues are important for distinguishing between agonist/antagonist binding, or that the agonist and antagonist peptides bind to two distinct sites within the C5aR.
引用
收藏
页码:171 / 177
页数:7
相关论文
共 32 条
[1]   cDNA cloning and characterization of rat C5a anaphylatoxin receptor [J].
Akatsu, H ;
Miwa, T ;
Sakurada, C ;
Fukuoka, Y ;
Ember, JA ;
Yamamoto, T ;
Hugli, TE ;
Okada, H .
MICROBIOLOGY AND IMMUNOLOGY, 1997, 41 (07) :575-580
[2]   Molecular evolution of the N-formyl peptide and C5a receptors in non-human primates [J].
Alvarez, V ;
Coto, E ;
Setien, F ;
GonzalezRoces, S ;
LopezLarrea, C .
IMMUNOGENETICS, 1996, 44 (06) :446-452
[3]   Cloning and preliminary pharmacological characterization of the anaphylatoxin C5a receptor in the rabbit [J].
Bachvarov, DR ;
Houle, S ;
Bachvarova, M ;
Bouthillier, J ;
St-Pierre, SA ;
Fukuoka, Y ;
Ember, JA ;
Marceau, F .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 128 (02) :321-326
[4]   ARGININE-206 OF THE C5A RECEPTOR IS CRITICAL FOR LIGAND RECOGNITION AND RECEPTOR ACTIVATION BY C-TERMINAL HEXAPEPTIDE ANALOGS [J].
DEMARTINO, JA ;
KONTEATIS, ZD ;
SICILIANO, SJ ;
VANRIPER, G ;
UNDERWOOD, DJ ;
FISCHER, PA ;
SPRINGER, MS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (27) :15966-15969
[5]  
DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446
[6]   Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity [J].
Finch, AM ;
Vogen, SM ;
Sherman, SA ;
Kirnarsky, L ;
Taylor, SM ;
Sanderson, SD .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (06) :877-884
[7]   Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a [J].
Finch, AM ;
Wong, AK ;
Paczkowski, NJ ;
Wadi, SK ;
Craik, DJ ;
Fairlie, DP ;
Taylor, SM .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (11) :1965-1974
[8]   Cloning and characterization of the guinea pig C5a anaphylatoxin receptor: interspecies diversity among the C5a receptors [J].
Fukuoka, Y ;
Ember, JA ;
Yasui, A ;
Hugli, TE .
INTERNATIONAL IMMUNOLOGY, 1998, 10 (03) :275-283
[9]  
Gasque P, 1997, AM J PATHOL, V150, P31
[10]  
GERARD C, 1992, J IMMUNOL, V149, P2600